Eli Lilly and Company has announced that donanemab met all primary and secondary endpoints for the 6-month primary...
BUSINESS News for MILLENIALAIRES
BUSINESS News for MILLENIALAIRES
Eli Lilly and Company has announced that donanemab met all primary and secondary endpoints for the 6-month primary...